{"id":124279,"date":"2026-01-03T08:30:19","date_gmt":"2026-01-03T08:30:19","guid":{"rendered":"https:\/\/www.europesays.com\/se\/124279\/"},"modified":"2026-01-03T08:30:19","modified_gmt":"2026-01-03T08:30:19","slug":"ozempic-kan-ge-ogonsjukdom-flera-fall-utreds","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/124279\/","title":{"rendered":"Ozempic kan ge \u00f6gonsjukdom \u2013 flera fall utreds"},"content":{"rendered":"<p>Novo Nordisks popul\u00e4ra l\u00e4kemedel Ozempic kan ge \u00f6gonsjukdomen naion, skriver TT. En svensk patient har f\u00e5tt r\u00e4tt till ers\u00e4ttning av L\u00e4kemedelsf\u00f6rs\u00e4kringen, som utreder totalt fem patienter f\u00f6r problemet.<\/p>\n<p>\u2013 Den eventuellt \u00f6kade risken vid Ozempicbehandling \u00e4r liten, men man ska beakta att den finns, s\u00e4ger Frank Tr\u00e4isk, \u00f6verl\u00e4kare p\u00e5 S:t Eriks \u00f6gonsjukhus, till nyhetsbyr\u00e5n.<\/p>\n<p>Novos l\u00e4kemedel Ozempic och Wegovy inneh\u00e5ller substansen semaglutid, som anv\u00e4nds f\u00f6r att behandla diabetes typ 2 respektive fetma. Under 2024 h\u00e4mtade 176 059 svenskar ut l\u00e4kemedel med semaglutid, skriver TT.<\/p>\n<p>Omni \u00e4r politiskt obundna och oberoende. Vi str\u00e4var efter att ge fler perspektiv p\u00e5 nyheterna. Har du fr\u00e5gor eller synpunkter kring v\u00e5r rapportering? <a href=\"https:\/\/omni.se\/ozempic-kan-ge-ogonsjukdom-flera-fall-utreds\/a\/mailto:redaktion@omni.se\" class=\"ArticleActions_contactLink__W2F1M\" rel=\"nofollow noopener\" target=\"_blank\">Kontakta redaktionen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisks popul\u00e4ra l\u00e4kemedel Ozempic kan ge \u00f6gonsjukdomen naion, skriver TT. En svensk patient har f\u00e5tt r\u00e4tt till&hellip;\n","protected":false},"author":2,"featured_media":124280,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,332,538,1206,34,31,33,32,30],"class_list":{"0":"post-124279","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-forskning-vetenskap","12":"tag-lakemedel-medicinteknik","13":"tag-novo-nordisk","14":"tag-se","15":"tag-svenska","16":"tag-sverige","17":"tag-sweden","18":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115830235023923426","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/124279","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=124279"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/124279\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/124280"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=124279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=124279"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=124279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}